Contribution ???of ???Cytochrome??? P450??2D6??to??3,4-Methylenedioxymethamphetamine Disposition in Humans
- 1 January 2005
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 44 (6), 649-660
- https://doi.org/10.2165/00003088-200544060-00006
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Quantitative determination of paroxetine and its 4-hydroxy-3-methoxy metabolite in plasma by high-performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studiesRapid Communications in Mass Spectrometry, 2003
- CYP2D6 deficiency, a factor in ecstasy related deaths?British Journal of Clinical Pharmacology, 2002
- Drug Interactions with Tobacco SmokingClinical Pharmacokinetics, 1999
- Characterization of the Translocation of Protein Kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/Ecstasy) in Synaptosomes: Evidence for a Presynaptic Localization Involving the Serotonin Transporter (SERT)Neuropsychopharmacology, 1998
- ParoxetineDrugs, 1998
- Clinically Relevant Pharmacology of Selective Serotonin Reuptake InhibitorsClinical Pharmacokinetics, 1997
- Pharmacokinetic-Pharmacodynamic Relationship of the Selective Serotonin Reuptake Inhibitors???Clinical Pharmacokinetics, 1996
- Protein Kinase C Modulates Regulation of the CYP1A1 Gene by the Aryl Hydrocarbon ReceptorPublished by Elsevier BV ,1996
- Adverse Reactions with 3,4-Methylenedioxymethamphetamine (MDMA; ???Ecstasy???)Drug Safety, 1996
- Pesticide-metabolizing enzymesToxicology Letters, 1995